Current Atherosclerosis Reports

, Volume 11, Issue 4, pp 281–288 | Cite as

Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease



The greatest clinical challenge in type 2 diabetes mellitus is the prevention of its long-term complications, many of which are of a cardiovascular nature. Despite the progress in cardiovascular risk management of diabetes patients using lipid-lowering and antihypertensive drugs, a substantial residual risk persists. Indeed, treated diabetes patients have a similar risk as untreated nondiabetic individuals. Although glycemic control through the use of antihyperglycemic agents improves microvascular complications, macrovascular disease risk is not reduced. These observations point to the need for additional therapeutic approaches in order to better control global cardiovascular risk. The peroxisome proliferator-activated receptor (PPAR) family members play major roles in the regulation of lipid and glucose metabolism and immune-inflammatory processes, making these transcription factors ideal targets for such therapeutic strategies. This review discusses our current knowledge of the effectiveness of PPAR-based therapeutics, focusing exclusively on cardiovascular disease in type 2 diabetes mellitus and the future prospects for novel generation of PPAR agonists.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Kearney PM, Blackwell L, Collins R, et al.: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117–125.PubMedCrossRefGoogle Scholar
  2. 2.
    Costa J, Borges M, David C, Vaz CA: Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006, 332:1115–1124.PubMedCrossRefGoogle Scholar
  3. 3.
    Miller M, Cannon CP, Murphy SA, et al.: Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724–730.PubMedCrossRefGoogle Scholar
  4. 4.
    Scott R, O’Brien R, Fulcher G, et al.: Effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 2009, 32:493–498.PubMedCrossRefGoogle Scholar
  5. 5.
    Barter P, Gotto AM, LaRosa JC, et al.: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301–1310.PubMedCrossRefGoogle Scholar
  6. 6.
    Balkau B, Shipley M, Jarrett RJ, et al.: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998, 21:360–367.PubMedCrossRefGoogle Scholar
  7. 7.
    Turner RC, Millns H, Neil HA, et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823–828.PubMedGoogle Scholar
  8. 8.
    Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.PubMedCrossRefGoogle Scholar
  9. 9.
    Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129–139.PubMedCrossRefGoogle Scholar
  10. 10.
    Fievet C, Fruchart JC, Staels B: PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 2006, 6:606–614.PubMedCrossRefGoogle Scholar
  11. 11.
    Staels B, Maes M, Zambon A: Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2008, 5:542–553.PubMedCrossRefGoogle Scholar
  12. 12.
    Ip E, Farrell G, Hall P, et al.: Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004, 39:1286–1296.PubMedCrossRefGoogle Scholar
  13. 13.
    Tenenbaum A, Fisman EZ, Boyko V, et al.: Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006, 166:737–741.PubMedCrossRefGoogle Scholar
  14. 14.
    Flavell DM, Ireland H, Stephens JW, et al.: Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes 2005, 54:582–586.PubMedCrossRefGoogle Scholar
  15. 15.
    Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M: Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2007, 56:1181–1186.PubMedCrossRefGoogle Scholar
  16. 16.
    Gerstein HC, Yusuf S, Bosch J, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096–1105.PubMedCrossRefGoogle Scholar
  17. 17.
    Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS: Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997, 100:530–537.PubMedCrossRefGoogle Scholar
  18. 18.
    Goldberg RB, Kendall DM, Deeg MA, et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547–1554.PubMedCrossRefGoogle Scholar
  19. 19.
    Nagashima K, Lopez C, Donovan D, et al.: Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005, 115:1323–1332.PubMedGoogle Scholar
  20. 20.
    Chappuis B, Braun M, Stettler C, et al.: Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007, 23:392–399.PubMedCrossRefGoogle Scholar
  21. 21.
    Duez H, Lamarche B, Uffelman KD, et al.: Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production. J Clin Endocrinol Metab 2008, 93:1722–1729.PubMedCrossRefGoogle Scholar
  22. 22.
    Chinetti G, Lestavel S, Bocher V, et al.: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7:53–58.PubMedCrossRefGoogle Scholar
  23. 23.
    Kawakami A, Osaka M, Aikawa M, et al.: Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res 2008, 103:1402–1409.PubMedCrossRefGoogle Scholar
  24. 24.
    Gizard F, Amant C, Barbier O, et al.: PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest 2005, 115:3228–3238.PubMedCrossRefGoogle Scholar
  25. 25.
    Gizard F, Nomiyama T, Zhao Y, et al.: The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation. Circ Res 2008, 103:1155–1163.PubMedCrossRefGoogle Scholar
  26. 26.
    Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905–910.Google Scholar
  27. 27.
    Keech A, Simes RJ, Barter P, et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849–1861.PubMedCrossRefGoogle Scholar
  28. 28.
    Deeg MA, Buse JB, Goldberg RB, et al.: Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007, 30:2458–2464.PubMedCrossRefGoogle Scholar
  29. 29.
    Dormandy JA, Charbonnel B, Eckland DJ et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.PubMedCrossRefGoogle Scholar
  30. 30.
    Nissen SE, Nicholls SJ, Wolski K, et al.: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008, 299:1561–1573.PubMedCrossRefGoogle Scholar
  31. 31.
    Davidson M, Meyer PM, Haffner S et al.: Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 2008, 117:2123–2130.PubMedCrossRefGoogle Scholar
  32. 32.
    Bajaj M, Suraamornkul S, Hardies LJ, et al.: Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007, 50:1723–1731.PubMedCrossRefGoogle Scholar
  33. 33.
    Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427–2443.PubMedCrossRefGoogle Scholar
  34. 34.
    Home PD, Jones NP, Pocock SJ, et al.: Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007, 24:626–634.PubMedCrossRefGoogle Scholar
  35. 35.
    Xiang AH, Peters RK, Kjos SL, et al.: Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006, 55:517–522.PubMedCrossRefGoogle Scholar
  36. 36.
    Elkeles RS, Diamond JR, Poulter C, et al.: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998, 21:641–648.PubMedCrossRefGoogle Scholar
  37. 37.
    Hiukka A, Westerbacka J, Leinonen ES, et al.: Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol 2008, 52:2190–2197.PubMedCrossRefGoogle Scholar
  38. 38.
    Rubins HB, Robins SJ, Collins D, et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597–2604.PubMedCrossRefGoogle Scholar
  39. 39.
    Libby P, Plutzky J: Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 2007, 99:27B–40B.PubMedCrossRefGoogle Scholar
  40. 40.
    Mazzone T, Meyer PM, Feinstein SB, et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572–2581.PubMedCrossRefGoogle Scholar
  41. 41.
    Maegawa H, Nishio Y, Nakao K, et al.: Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. Endocr J 2007, 54:613–618.PubMedCrossRefGoogle Scholar
  42. 42.
    Nishio K, Sakurai M, Kusuyama T, et al.: A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006, 29:101–106.PubMedCrossRefGoogle Scholar
  43. 43.
    Erdmann E, Dormandy JA, Charbonnel B, et al.: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007, 49:1772–1780.PubMedCrossRefGoogle Scholar
  44. 44.
    Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.PubMedCrossRefGoogle Scholar
  45. 45.
    Ansquer JC, Foucher C, Aubonnet P, Le Malicot K: Fibrates and microvascular complications in diabetes—insight from the FIELD study. Curr Pharm Des 2009, 15:537–552.PubMedCrossRefGoogle Scholar
  46. 46.
    Shen LQ, Child A, Weber GM, et al.: Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol 2008, 126:793–799.PubMedCrossRefGoogle Scholar
  47. 47.
    Nakamura T, Ushiyama C, Shimada N, et al.: Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000, 14:250–254.PubMedCrossRefGoogle Scholar
  48. 48.
    Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA: Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007, 72:1367–1373.PubMedCrossRefGoogle Scholar
  49. 49.
    Genest J, Frohlich J, Steiner G: Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol 2004, 93:848–853.PubMedCrossRefGoogle Scholar
  50. 50.
    Niemeyer NV, Janney LM: Thiazolidinedione-induced edema. Pharmacotherapy 2002, 22:924–929.PubMedCrossRefGoogle Scholar
  51. 51.
    Guan Y, Hao C, Cha DR, et al.: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005, 11:861–866.PubMedCrossRefGoogle Scholar
  52. 52.
    Vallon V, Hummler E, Rieg T, et al.: Thiazolidinedioneinduced fluid retention is independent of collecting duct {alpha}ENaC activity. J Am Soc Nephrol 2009 (in press).Google Scholar
  53. 53.
    Grey A, Bolland M, Gamble G, et al.: The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007, 92:1305–1310.PubMedCrossRefGoogle Scholar
  54. 54.
    Buse JB, Bigger JT, Byington RP, et al.: Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007, 99:21i–33i.PubMedCrossRefGoogle Scholar
  55. 55.
    Seber S, Ucak S, Basat O, Altuntas Y: The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract 2006, 71:52–58.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Institut PasteurLille CedexFrance

Personalised recommendations